Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €1.74 EUR
Change Today +0.209 / 13.64%
Volume 4.4K
IM3 On Other Exchanges
As of 2:11 PM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

immunomedics inc (IM3) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/15 - €4.75
52 Week Low
09/29/15 - €1.34
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IMMUNOMEDICS INC (IM3)

immunomedics inc (IM3) Related Bloomberg News

View More Bloomberg News

immunomedics inc (IM3) Related Businessweek News

No Related Businessweek News Found

immunomedics inc (IM3) Details

Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases. The company is developing Yttrium-90-labeled clivatuzumab tetraxetan, which is in Phase III registration study used for the treatment of pancreatic cancer. It is also developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAM5-SN-38 ADC that is in Phase II trials for the treatment of metastatic colorectal cancer; and epratuzumab, which is in two Phase III clinical trials for the treatment of systemic lupus erythematosus. Its early-stage products include Veltuzumab, a humanized monoclonal antibody targeting CD20 receptors on B lymphocytes for the treatment of non-Hodgkin lymphoma (NHL) and autoimmune diseases; Milatuzumab, a humanized monoclonal antibody targeting tumors that expresses the CD74 antigen, which is in Phase 1 studies; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled anti-CD22 investigational product candidate for patients with NHL or acute lymphoblastic leukemia; and IMMU-114, a novel humanized antibody for the treatment of patients with B-cell cancers. The company also provides LeukoScan, a diagnostic imaging product for diagnostic imaging to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.

123 Employees
Last Reported Date: 08/19/15
Founded in 1982

immunomedics inc (IM3) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $618.9K
Founder and Chairman of the Board
Total Annual Compensation: $584.5K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $235.5K
Compensation as of Fiscal Year 2014.

immunomedics inc (IM3) Key Developments

Immunomedics Inc. Reports Interim Phase 2 Results with Sacituzumab Govitecan in Lung Cancers

Immunomedics Inc. announced that sacituzumab govitecan, the Company's lead investigational antibody-drug conjugate (ADC), continues to produce durable responses in patients with metastatic lung cancer who had relapsed or were refractory to their last cancer therapy. At the time of this analysis, a total of 57 patients with metastatic lung cancer (28 non-small-cell lung cancer (NSCLC) and 29 small-cell lung cancer (SCLC)) had been enrolled into this multicenter study at doses ranging from 8-18 mg/kg given on days 1 and 8 every 21 days. The median number of prior lines of therapy in the NSCLC and SCLC patients was 3 and 2.5, respectively. Across all tumor types, 12 mg/kg was declared the maximal tolerated dose and 10 mg/kg declared the recommended Phase 2 dose. Accrual at 10 mg/kg continues. Treatment response in lung cancer patients administered doses of =12 mg/kg was assessed by computed tomography using the rules set by the Response Evaluation Criteria In Solid Tumors (RECIST 1.1). In NSCLC, the most common type of lung cancer, 6 of 19 patients achieved an objective response (objective response rate = 32%). In SCLC, 6 of 20 patients achieved an objective response (objective response rate = 30%). In the 10 mg/kg cohorts, the objective response (partial response) rates in NSCLC and SCLC were 3/10 (30%) and 3/5 (60%), respectively. In NSCLC, the interim median progression-free survival (PFS), which is the length of time patients are living without their cancer progressing, was 5.4 months for those patients receiving sacituzumab govitecan at the dose level of 10 mg/kg. At the time of analysis, fifty-six % of NSCLC patients in this dose group had experienced a PFS event. For patients with SCLC, interim median PFS was 4.6 months at the 10 mg/kg dose level. At the time of analysis, eighty-three % of SCLC patients in this dose group had experienced a PFS event. Overall survival (OS) data were too early to report. Sacituzumab govitecan is a first-in-class antibody-drug conjugate (ADC) developed by the Company by conjugating the moderately-toxic drug, SN-38, site-specifically and at a high ratio of drug to antibody, to a humanized antibody that targets the TROP-2 receptor expressed by many solid cancers. SN-38 is the active metabolite of irinotecan (Camptosar), which is used to treat certain solid cancers, particularly metastatic colorectal cancers, as a part of combination therapies, so its pharmacology and properties are well-known. In addition, the ADC also continues to demonstrate a highly tolerable and easily managed toxicity profile, despite repeated dosing. In the 31 lung cancer patients receiving sacituzumab govitecan at the dose of 10 mg/kg, the major toxicity reported was 10% Grades 3 and 4 neutropenia. Remarkably, there was no reported incidence of Grade 3 or 4 diarrhea, which is a major side effect with irinotecan. At 10 mg/kg 13% of lung cancer patients required a dose reduction in sacituzumab govitecan.

Immunomedics Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2015

Immunomedics Inc. reported consolidated earnings results for the fourth quarter and full year ended June 30, 2015. Total revenues for the fourth quarter of fiscal year 2015, which ended on June 30, 2015, were $2.4 million as compared to total revenues of $1.2 million for the same quarter last fiscal year. The increase of $1.2 million in total revenues this quarter was primarily due to a $1.0 million license fee revenue earned upon reaching a clinical milestone in the company's collaboration agreement, as amended, with Bayer (formerly Algeta ASA). Net loss attributable to the company’s stockholders was $12.4 million, or $0.13 per basic and diluted share, compared with a net loss attributable to the company’s stockholders of $11.8 million, or $0.13 per basic and diluted share for the same quarter in fiscal 2014. The increase in net loss this quarter was primarily due to the increase in research and development expenses and interest expense, partially offset by the decrease in legal and professional fees. Loss before income tax expense was $12,411,362 against $11,866,936 a year ago. Total revenues for fiscal year 2015 were $5.7 million as compared to $9.0 million for fiscal year 2014, representing a decrease of $3.3 million or 37%. The decrease in total revenues this fiscal year primarily resulted from $4.6 million of license fee revenue earned from the Bayer Collaboration Agreement during fiscal 2014, which was partially offset by the Agreement's $1.0 million clinical milestone payment in fiscal year 2015. Net loss attributable to the company’s stockholders for the fiscal year ended June 30, 2015 was $48.0 million, or $0.51 per basic and diluted share, as compared to net loss attributable to the company’s stockholders of $35.4 million, or $0.42 per basic and diluted share, in fiscal year 2014. The increase in net loss of $12.6 million this fiscal year was primarily due to increased research and development costs attributable to clinical trials, increased legal and professional fees, interest expense, and lower license fee revenue from Bayer. Loss before income tax expense was $48,065,742 against $35,523,387 a year ago.

Immunomedics Inc. Appoints Arthur S. Kirsch as Director

Immunomedics Inc. announced the appointment of Arthur S. Kirsch, to its Board of Directors. Mr. Kirsch has over 30 years of experience working in the equity capital markets and has extensive knowledge of the healthcare and life sciences field. He is Chairman of the Board of Pozen Inc. since June 1, 2015, serving as a Director since 2004.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IM3:GR €1.74 EUR +0.209

IM3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IM3.
View Industry Companies

Industry Analysis


Industry Average

Valuation IM3 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 30.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOMEDICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at